enGene Therapeutics Inc. (ENGN)
Nasdaq: ENGN · Biological Products, (No Diagnostic Substances) · Saint-Laurent, QC · filing with the SEC since 2023
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in October.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Period ending | Oct 31, 2025 | Oct 31, 2024 | Oct 31, 2023 | Oct 31, 2022 |
| Report filed | Dec 22, 2025 | Dec 19, 2024 | Jan 29, 2024 | · |
| Research and development | 94,480 | 38,315 | 16,458 | 15,467 |
| General and administrative | 28,685 | 23,982 | 9,602 | 3,960 |
| Total operating expenses | 123,165 | 62,297 | 26,060 | 19,427 |
| Operating income | -123,165 | -62,297 | -26,060 | -19,427 |
| Interest expense | 2,994 | 2,798 | 4,953 | 1,423 |
| Interest and investment income | 9,426 | 10,413 | 1,117 | 129 |
| Other income (expense), net | -569 | -113 | -129 | -662 |
| Total non-operating income (expense) | 5,863 | 7,136 | -73,840 | -5,013 |
| Income before income taxes | -117,302 | -55,161 | -99,900 | -24,440 |
| Income tax expense | 0 | -19 | 17 | 22 |
| Net income including non-controlling interests | -117,302 | -55,142 | -99,917 | -24,462 |
| Net income | -117,302 | -55,142 | -99,917 | -24,462 |
| Net income to common shareholders | -117,302 | -55,142 | -104,739 | -29,024 |
| Earnings per share, basic | 2.29 | 1.46 | 151.22 | 44.30 |
| Earnings per share, diluted | 2.29 | 1.46 | 151.22 | 44.30 |
| Weighted average shares, basic | 51,119,479 | 37,782,346 | 692,609 | 655,153 |
| Weighted average shares, diluted | 51,119,479 | 37,782,346 | 692,609 | 655,153 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperating
us-gaap:InterestExpenseInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding